What is the recommended washout period, if any, when switching from escitalopram (Lexapro) to bupropion (Wellbutrin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Lexapro (Escitalopram) to Wellbutrin (Bupropion)

No washout period is required when switching from escitalopram to bupropion—you can start bupropion immediately after stopping Lexapro, though a gradual taper of escitalopram over 10-14 days is recommended to minimize discontinuation symptoms.

Direct Switch Strategy

The FDA labeling for both medications provides clear guidance on this transition:

  • Bupropion (Wellbutrin) does NOT require a washout period when switching from SSRIs like escitalopram 1. The 14-day washout requirement only applies when switching to or from MAOIs, not between different antidepressant classes 1.

  • Escitalopram (Lexapro) can be discontinued without a mandatory drug-free interval before starting bupropion, as these medications work through different mechanisms (serotonin reuptake inhibition vs. dopamine/norepinephrine reuptake inhibition) 2.

Recommended Tapering Approach

While no washout is needed, taper escitalopram gradually to avoid discontinuation syndrome 3, 4:

  • Reduce escitalopram dose over 10-14 days before complete cessation 4
  • For patients on 20 mg daily: reduce to 10 mg for 7 days, then discontinue
  • For patients on 10 mg daily: reduce to 5 mg for 7 days, then discontinue
  • Start bupropion on the same day you begin the taper or immediately after the last escitalopram dose

Bupropion Initiation During Taper

Begin bupropion at 150 mg once daily in the morning 1:

  • After 4 days, may increase to target dose of 300 mg once daily
  • Take in the morning to minimize insomnia risk 4
  • Can be started while tapering escitalopram—no drug interaction concerns

Critical Monitoring Points

Monitor closely for discontinuation symptoms in the first 1-2 weeks 2:

  • Dizziness, fatigue, headaches, nausea
  • Anxiety, irritability, sensory disturbances
  • These symptoms indicate escitalopram withdrawal, not bupropion side effects

Watch for neuropsychiatric changes with bupropion initiation 5:

  • Increased agitation or activation (bupropion is activating) 4
  • Worsening depression or suicidal ideation
  • Insomnia (give second dose before 3 PM if using twice-daily formulation) 4

Common Pitfalls to Avoid

Do not use alternate-day dosing when tapering escitalopram—this causes severe receptor occupancy fluctuations and worsens withdrawal symptoms 6, 7. Use daily reduced doses instead.

Do not confuse this switch with MAOI transitions—the 14-day washout only applies to MAOIs, not SSRI-to-bupropion switches 1.

Contraindications for bupropion: Do not use in patients with seizure disorders, eating disorders (bulimia/anorexia), or those abruptly discontinuing alcohol or benzodiazepines 5, 1.

Why This Approach Works

Escitalopram and bupropion have no significant pharmacodynamic interactions—escitalopram primarily affects serotonin while bupropion affects dopamine and norepinephrine 8. The gradual taper of escitalopram prevents withdrawal symptoms while bupropion provides immediate antidepressant coverage, avoiding a treatment gap that could lead to depressive relapse 9, 7.

References

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Guideline

smoking cessation, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Research

Switching and stopping antidepressants.

Australian prescriber, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.